No, it’s not futuristic fiction: a contact lens with technology that imitates the effect of the human iris. Helping people with a damaged or missing iris to improve their sight and patients with chronic migraine to reduce their light sensitivity. It’s a hi-tech accomplishment that Ghent University and imec will now market: the spin-off Azalea Vision will continue developing and commercialising the contact lens.
That blinking in the morning as a reaction to the first bright light. We’re all familiar with it. That’s a sign that your irises are hard at work. They regulate the amount of light entering the eye. These adjustments are why you can see both when there’s lots of light and when night falls.
At least that’s how it’s meant to work, but for lots of unlucky people it’s not the case. An estimated 20 million people around the world suffer from an eye complaint, including a damaged or missing iris. This makes the eye much more sensitive to light, causing all kinds of consequences for their vision. They see less sharply, struggle to perceive light and, in some cases, it can even result in low vision and blindness.
Artificial iris
But there is light at the end of the tunnel. Researchers at Ghent University and research centre imec have designed an artificial iris that imitates the human model. Picture it as an electronic contact lens that can alter the size of the pupil. Something remarkable: the lens not only regulates how much light can enter, but also the depth of field, just like a real camera.
And that’s the big difference compared to solutions already on the market. Static contact lenses with a fixed iris, artificial iris implants, or glasses with variable transparency can resolve part of the problem, but are not yet able to imitate every function of the iris. This means that the amount of light coming in is adjusted, but patients still fail to see sharply, for example.
LCD technology
So how does this kind of artificial iris actually work? “The lens, applied like any normal contact lens, contains LCD technology which can copy the movements of the iris with ring-shaped pixels”, explains professor Andrés Vásquez Quintero. “Movements are controlled by ultra-thin electronics, completed with a blinking detector. A photodiode, a kind of light detector, determines exactly how much light may enter.”
Not only that, the lens also consumes very limited energy, and can be charged at night on your bedside table thanks to an integrated NFC chip.
Microsystem technology
The technology driving the artificial iris is an ingenious example of microsystem technology. Integrating a range of technologies and expertise, such as flexible electronics, liquid-crystal technology, low-power chip design, photonics and hybrid integration. “With this kind of combination you could only expect an ultra compact and autonomous system, and this is certainly the case with this artificial iris”, explains business developer Frederik Leys.
Microsystem technology is big science, but also big business, and there is much demand from the commercial world to team up in the research. Ghent University is witnessing growing interest as well. Leading not only to interesting partnerships, but also to promising spin-offs within the domain.
Funding
Among them is Azalea Vision, a spin-off of imec and Ghent University. This company will continue developing the prototype of the artificial iris, allowing it to undergo clinical validation.
The ambition is to launch a contact lens on the market which offers a solution for all eye complaints causing a reduction in light sensitivity and depth of field. To fund this ambition Azalea Vision has already raised eight million euros, including almost two million euros from public funding coming from VLAIO.
Read also
Is a stool transplant a potential treatment for Parkinson’s?
A recent study into Parkinson’s disease has shown that a stool transplant may constitute a new and valuable treatment of the disease. “It offers a potentially safe, effective and cost-efficient way of alleviating the symptoms and improving the quality of life of millions. A 'bacterial pill' might replace the stool transplant in the future. But more research is needed.”
Researcher fights unpleasant side effect of breast cancer treatment with innovative contrast agent
1 in 9 women in Belgium will develop breast cancer. The treatment is often accompanied by the injection of a radioactive liquid and blue dye that can turn the breast blue for years. To avoid this side effect, Ghent University researcher Loren Deblock is working on a new contrast agent made of... nanocrystals.
Is it easier to live with HIV than with the stigma that surrounds it?
HIV, the virus that causes AIDS, surfaced in the eighties. Long gone are the times when the virus was a sure death sentence. Still, even after all these years the stubborn stigma that surrounds HIV persists. Why is that and what can be done about it?
No more painful mammograms thanks to researchers in Ghent?
Researchers around the world are looking for innovative ways to detect and treat breast cancer. So are experimental oncologist An Hendrix and medical oncologist Hannelore Denys, two top researchers from Ghent.
